Anal canal and colorectal cancer: Current features: IV - colon cancer - clinical, epidemiological, and preventive aspects;Câncer ano-reto-cólico: Aspectos atuais IV - Câncer de cólon - Fatores clínicos, epidemiológicos e preventivos

Revista Brasileira de Coloproctologia

Volumn 28, Issue 3, 2008, Pages 378-385

  Santos Jr , Júlio César M ^a  

^a Instituto de Medicina   (Brazil)

Author keywords

Cancer screening; Fecal occult blood; Preventive strategy

Indexed keywords

EID: 58149189928     PISSN: 01019880     EISSN: None     Source Type: Journal    
DOI: 10.1590/s0101-98802008000300019     Document Type: Article

References (58)

1. Society AC. Cancer Facts & Figures. 2008. pp. 12-13.
2. Cress RD, Morris C, Ellison GL, Goodman MT. Secular changes in colorectal cancer incidence by subsite, stage at diagnosis, and race/ ethnicity, 1992-2001. Cancer 2006; 107(5 Suppl):1142-52.
3. Ferlay J, Autier P, Boniol M, et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007; 18(3):581-92.
4. Cancer MdSI-INd. Incidência de Cancer no Brasil - Estimativa de 2008. Vol. 2008. Rio de janeiro, 2008.
5. Santos Jr JCM. Câncer ano-reto-cólico: Aspectos atuais II - Cêncer colorretal: fatores de riscos e prevenção. Rev bras Coloproctol 2007; 27(4):459-473.
6. Society AC. Cancer Facts & Figures. 2007. pp. 1-56. 7. Fabre E, Spano JP, Atlan D, et al. [Cancer of the colon: an update]. Bull Cancer 2000; Suppl 4:5-20.
7. Abrapeci. Associação Brasileira de Prevenção do Câncer do Intestino. 2008.
8. Vainio H, Miller AB. Primary and secondary prevention in colorectal cancer. Acta Oncol 2003; 42(8):809-15.
9. Goligher J. Surgery of the Anus, Rectum and Colon. In John Goligher, Hebert Duthie, Nixon H, eds. London: Baillière Tindall, 1984. pp. 1161.
10. Gomez D, Dalal Z, Raw E, et al. Anatomical distribution of colorectal cancer over a 10 year period in a district general hospital: is there a true "rightward shift"? Postgrad Med J 2004; 80(949):667-9.
11. Patel K, Hoffman NE. The anatomical distribution of colorectal polyps at colonoscopy. J Clin Gastroenterol 2001; 33(3):222-5.
12. Obrand DI, Gordon PH. Continued change in the distribution of colorectal carcinoma. Br J Surg 1998; 85(2):246-8.
13. Erkek B, Ozkan N, Bayar S, et al. Subsite distribution of colorectal carcinoma and implications for screening; a retrospective audit of 1771 cases. Hepatogastroenterology 2007; 54(73):77-80.
14. Takada H, Ohsawa T, Iwamoto S, et al. Changing site distribution of colorectal cancer in Japan. Dis Colon Rectum 2002; 45(9):1249-54.
15. McFarlane ME, Rhoden A, Fletcher PR, Carpenter R. Cancer of the colon and rectum in a Jamaican population: diagnostic implications of the changing frequency and subsite distribution. West Indian Med J 2004; 53(3):170-3.
16. Mensink PB, Kolkman JJ, Van Baarlen J, Kleibeuker JH. Change in anatomic distribution and incidence of colorectal carcinoma over a period of 15 years: clinical considerations. Dis Colon Rectum 2002; 45(10):1393-6.
17. Nelson RL, Dollear T, Freels S, Persky V. The relation of age, race, and gender to the subsite location of colorectal carcinoma. Cancer 1997; 80(2):193-7.
18. Qing SH, Rao KY, Jiang HY, Wexner SD. Racial differences in the anatomical distribution of colorectal cancer: a study of differences between American and Chinese patients. World J Gastroenterol 2003; 9(4):721-5.
19. Shavers VL. Racial/ethnic variation in the anatomic subsite location of in situ and invasive cancers of the colon. J Natl Med Assoc 2007; 99(7):733-48.
20. Kurome M, Kato J, Nawa T, et al. Risk factors for high-grade dysplasia or carcinoma in colorectal adenoma cases treated with endoscopic polypectomy. Eur J Gastroenterol Hepatol 2008; 20(2):111-7.
21. Nawa T, Kato J, Kawamoto H, et al. Differences between right- and left-sided colon cancer in patient characteristics, cancer morphology and histology. J Gastroenterol Hepatol 2008; 23(3):418-23.
22. Sarli L, Michiara M, Sgargi P, et al. The changing distribution and survival of colorectal carcinoma: an epidemiological study in an area of northern Italy. Eur J Gastroenterol Hepatol 2005; 17(5):567-72.
23. Gervaz P, Bucher P, Neyroud-Caspar I, et al. Proximal location of colon cancer is a risk factor for development of metachronous colorectal cancer: a population-based study. Dis Colon Rectum 2005; 48(2):227-32.
24. Almeida FF, Araujo SE, Santos FP, et al. Colorectal cancer screening. Rev Hosp Clin Fac Med Sao Paulo 2000; 55(1):35-42.
25. Faivre J, Bonithon-Kopp C. Chemoprevention of colorectal cancer. Recent Results Cancer Res 1999; 151:122-33.
26. Conférence de consensus. Prévention, dépistage et prise en charge des cancers du côlon. Gastroenterol Clin Biol 1999; 22:5275-88.
27. Thomson CA, LeWinn K, Newton TR, et al. Nutrition and diet in the development of gastrointestinal cancer. Curr Oncol Rep 2003; 5(3):192-202.
28. Kargman SL, O'Neill GP, Vickers PJ, et al. Expression of prostaglandin G/ H synthase-1 and -2 protein in human colon cancer. Cancer Res 1995; 55(12):2556-9.
29. Benamouzig R. [Do aspirin or nonsteroidal anti-inflammatory drugs decrease the risk of colorectal cancer?]. Gastroenterol Clin Biol 1998; 22(3 Suppl):S22-7.
30. Kune GA, Kune S, Watson LF. Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer Res 1988; 48(15):4399-404.
31. Rosenberg L, Palmer JR, Zauber AG, et al. A hypothesis: nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer. J Natl Cancer Inst 1991; 83(5):355-8.
32. Peleg, II, Maibach HT, Brown SH, Wilcox CM. Aspirin and nonsteroidal anti-inflammatory drug use and the risk of subsequent colorectal cancer. Arch Intern Med 1994; 154(4):394-9.
33. Muscat JE, Stellman SD, Wynder EL. Nonsteroidal antiinflammatory drugs and colorectal cancer. Cancer 1994; 74(7):1847-54.
34. Gann PH, Manson JE, Glynn RJ, et al. Low-dose aspirin and incidence of colorectal tumors in a randomized trial. J Natl Cancer Inst 1993; 85(15):1220-4.
35. Giovannucci E, Egan KM, Hunter DJ, et al. Aspirin and the risk of colorectal cancer in women. N Engl J Med 1995; 333(10):609-14.
36. Vasen HF, Mecklin JP, Khan PM, Lynch HT. The International Collaborative Group on HNPCC. Anticancer Res 1994; 14(4B):1661-64.
37. Vasen HF, Watson P, Mecklin JP, Lynch CF. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 1999; 116(6):1453-56.
38. Dunkop M. Guidance on gastrointestinal surveillance for hereditary non-polyposis colorectal cancer, familial adenomotous polyposis, juvenile polyposis, and Peutz-Jeghers syndrome. Gut 2002; 51(5):12-27.
39. Halbert CH, Lynch H, Main D, et al. Colon Cancer Screening Practices Following Genetic Testing for Hereditary Nonpolyposis Colon Cancer (HNPCC) Mutations Arch Intern Med 2004; 164(17):1881-87.
40. Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004; 96(4):261-68.
41. Dove-Edwin I, Sasieni P, Adams J, Thomas HJW. Prevention of colorectal cancer by colonoscopic surveillance in individuals with a family history of colorectal cancer: 16 year, prospective, follow-up study. BMJ 2005; 331:1047-49.
42. Brown GJE, Aittomäki K. Cancer Risk in Young Women at Risk of Hereditary Nonpolyposis Colorectal Cancer: Implications for Gynecologic Surveillance. Gynecol Oncology 2001; 80(3):346-49.
43. Dove-Edwin I, Boks D, Goff S, al. e. The outcome of endometrial carcinoma surveillance by ultrasound scan in women at risk of hereditary nonpolyposis colorectal carcinoma and familial colorectal carcinoma. Cancer 2002; 94(6):1708-12.
44. Winawer SJ, O'Brien MJ, Waye JD, et al. Risk and surveillance of individuals with colorectal polyps. Bull WHO 1990; 68:7789.
45. de Jong AE, Morreau H, Nagengast FM, et al. Prevalence of Adenomas Among Young Individuals at Average Risk for Colorectal Cancer. Am J Gastroenterol. 2005; 100(1):139-43.
46. Miller MP, Stanley TV. Results of a mass screening program for colorectal cancer. Arch Surg 1988; 123(1):63-65.
47. Towler BP, Irwig L, Glasziou P, et al. Screening for colorectal cancer using the faecal occult blood test, hemoccult. Cochrane Database Syst Rev 2000; 1(CD001216).
48. Faivre J. State of the art in colorectal cancer screening. Gut 2000; 47(Suppl 3):A38.
49. Heresbach D, Manfredi S, D'halluin PN, et al. Review in depth and meta-analysis of controlled trials on colorectal cancer screening by faecal occult blood test. Eur J Gastroenterol Hepatol 2006; 18(4):427-33.
50. Mandel JS, Church TR, Bond JH, et al. The effect of fecal occult blood screening on the incidence of colorectal cancer. N Engl J Med 2000; 343(22):1603-7.
51. James AS, Campbell MK, Hudson MA. Perceived barriers and benefits to colon cancer screening among african americans in North Carolina: How does perception relate to screening behavior? Cancer Epidemiol, Biomarkers & Prevention 2002; 11:529-34.
52. Nagamine M, Phillips K, Haas J, Liang SY. Predictors of Utilization of Colorectal Cancer Screening Tests (CRC) and Adherence to the Screening Guidelines among Low-Income Populations. Abstr AcademyHealth Meet 2005; 22(abst 4007):4007.
53. Launoy G, Herbert C, Vallee JP, et al. [Mass screening for colorectal cancer in France. Experience in 165,000 people in the department of Calvados]. Gastroenterol Clin Biol 1996; 20(3):228-36.
54. Flachs A. [Self-evaluation of the dynamics of distribution of the Hemoccult II test in the practice of general medicine for departmental mass screening]. Gastroenterol Clin Biol 1995; 19(4):457-8.
55. Bretagne JF, Manfredi S, Heresbach D. Colorectal cancer mass screening: present and future. Presse Med 2007; 37:363-66.
56. Lindholm E, Brevinge H, Haglind E. Survival benefit in a randomized clinical trial of faecal occult blood screening for colorectal cancer. Br J Surg 2008; 95(8):1029-36.
57. Hewitson P, Glasziou P, Watson E, et al. Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. Am J Gastroenterol 2008; 103(6):1541-49.
58. Faivre J, Tazi MA, Milan C, et al. Controlled trial of faecal occult blood screnning for colorectal cancer in Burgundy (Franc): results of the first 9 years. Gastroenterology 1999; 116:A400.